Vesnarinone represses the fibrotic changes in murine lung injury induced by bleomycin

International Journal of Biological Sciences

Volumn 5, Issue 4, 2009, Pages 304-310

  Inage, Minoru ^a   Nakamura, Hidenori ^a   Saito, Hiroshi ^a   Abe, Shuichi ^a   Hino, Toshihiko ^a   Takabatake, Noriaki ^a   Terashita, Kyoko ^a   Ogura, Manabu ^a   Kato, Shuichi ^a   Hosokawa, Tetsumi ^b   Sata, Makoto ^a,c   Tomoike, Hitonobu ^a,c  

^a YAMAGATA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Acute lung injury; Bleomycin; Chemokine; Pulmonary fibrosis; Vesnarinone

Indexed keywords

MURINAE; MUS;

BLEOMYCIN; CYTOKINE; HYALURONIC ACID; HYDROXYPROLINE; PIPERANOMETOZINE; QUINOLINE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; CYTOLOGY; DIET; DRUG ANTAGONISM; DRUG EFFECT; HOSPITALIZATION; INSTITUTE FOR CANCER RESEARCH MOUSE; LUNG; LUNG FIBROSIS; LUNG LAVAGE; MALE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DIET; HYALURONIC ACID; HYDROXYPROLINE; LUNG; MALE; MICE; MICE, INBRED ICR; PULMONARY FIBROSIS; QUINOLINES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 66149183265     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.304     Document Type: Article

References (36)

1. Panos RJ, King TE. Idiopathic pulmonary fibrosis. In: Lynch JP, DeRemee RA, eds. Immunologically mediated pulmonary fibrosis. Philadelphia: Lippincott; 1991: 1-39.
2. Visscher DW, Myers JL. Histologic spectrum of idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 322-329.
3. Wolff G, Crystal RG. Biology of pulmonary fibrosis. In: Crystal RG, West JB, Barnes PJ, Weibel ER, eds. The Lung. Philadelphia: Lippincott; 1997: 2509-2524.
4. Alan F, Goldstein RH. Animal models of pulmonary fibrosis. In: Crystal RG, West JB, Barnes PJ, Weibel ER, eds. The Lung. Philadelphia: Lippincott; 1997: 2525-2536.
5. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 362-382.
6. Nakamura H, Sato S, Takahashi K. Effect of vitamin E deficiency on bleomycin-induced pulmonary fibrosis in the hamster. Lung 1988; 166: 161-176.
7. Hosokawa T, Mori T, Fujiki H, Kinoshita S, Takemoto K, Imaizumi T, Noda T, Ohura M, Tominaga M, Yabuuchi Y. Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action. Heart Vessels 1992; 7: 66-75.
8. Itoh H, Kusagawa M, Shimomura A, Suga T, Ito M, Konishi T, Nakano T. Ca2+-dependent and Ca2+-independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors. Eur J Pharmacol 1993; 240: 57-66.
9. Toyama G, Kamiya K, Cheng J, Lee JK, Suzuki R, Kodama I. Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K current. Circulation 1997; 18: 3696-3703.
10. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest 1994; 94: 1212-1217.
11. Matsui S, Matsumori A, Sasayama S. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sci 1994; 55: 1735-1741.
12. Sasayama S, Matsumori A. Vesnarinone: a potential cytokine inhibitor. J Cardiac Fail 1996; 2: 251-258.
13. Takeuchi K, del Nido PJ, Ibrahim AE, Cao-Danh H, Friehs I, Glynn P, Poutias D, Cowan DB, McGowan FX Jr. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome. Thorac Cardiovasc Surg 1999; 117: 375-382.
14. Miyamoto G, Sasabe H. Pharmacokinetics of a new positive inotropic agent, 3, 4-Dihydro-6[4(3, 4-dimethoxybenzoyl) -1-piperazinyl] S-2 (1H) -quinolinone (OPC-8212), in the rat, rabbit, beagle dog and rhesus monkey. Arzneim -Forsch /Drug Res 1984; 34: 394-402.
15. Kruger NJ. The Bradford method for protein quantitation. Methods Mol Biol 1994; 32: 9-15.
16. Ashcroft T, Simpson JM, Timbell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-470.
17. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 1961; 93: 440-447.
18. Ohnishi A, Ishizaki T. Pharmacokinetic profile of OPC=8212 in human: a new, non-glycoside, inotropic agent. J Clin Pharmacol 1988; 28: 719-726.
19. Martin C, Papazian L, Payan MJ, Saux P, Gouin F. Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients. Chest 1995; 107: 196-200.
20. Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg 2008; 34: 878-881.
21. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994; 89: 955-958.
22. Matsumori A, Okada I, Shioi T, Furukawa Y, Nakamura T, Ono K, Iwasaki A, Sasayama S. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sci 1996; 59: 121-125.
23. Hattori Y, So S, Hattori S, Kasai K, Shimoda S. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovasc Res 1995; 30: 187-192.
24. Oyaizu N, McCloskey TW, Than S, Pahwa S. Inhibition of CD4 cross-linking-induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Blood 1996; 87: 2361-2368.
25. Manna SK, Aggarwal BB. Vesnarinone suppresses TNF-induced activation of NF-êB, c-Jun kinase, and apoptosis. J Immunol 2000; 164: 5815-5825.
26. Miotla JM, Teixeira MM, Hellewell PG. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am J Respir Cell Mol Biol 1998; 18: 411-420.
27. Nakamura H, Hino T, Kato S, Shibata Y, Takahashi H, Tomoike H. Tumor necrosis factor receptor gene expressions and shedding in human whole lung tissue and pulmonary epithelium. Eur Respir J 1996; 9: 1643-1647.
28. Hino T, Nakamura H, Abe S, Saito H, Inage M, Terashita K, Kato S, Tomoike H. Hydrogen peroxide enhances shedding of type I soluble tumor necrosis factor receptor from pulmonary epithelial cells. Am J Respir Cell Mol Biol 1999; 20: 122-128.
29. Saldiva PH, Delmonte VC, de Carvalho CR, Kairalla RA, Auler Junior JO. Histochemical evaluation of lung collagen content in acute and chronic interstitial diseases. Chest 1989; 95: 953-957.
30. Sato Y, Matsumori A, Sasayama S. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol 1995; 27: 2265-2273.
31. Ueki N, Taguchi T, Takahashi M, Adachi M, Ohkawa T, Amuro Y, Hada T, Higashino K. Inhibition of hyaluronan synthesis by vesnarinone in cultured human myofibroblasts. Biochim Biophys Acta 2000; 1495: 160-167.
32. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxyfylline inhibits TNF-(production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159: 508-511.
33. Hagimoto N, Kuwano K, Kunitake R, Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 1997; 16: 91-101.
34. Kawamata H, Nakashiro K, Uchida D, Hino S, Omotehara F, Yoshida H, Sato M. Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. Br J Cancer 1998; 77: 71-78.
35. Sato M, Kawamata H, Harada K, Nakashiro K, Ikeda Y, Gohda H, Yoshida H, Nishida T, Ono K, Kinoshita M, Adachi M. Induction of cyclin-dependent kinase inhibitor, p21 WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl]-1-piperazinyl]-2(1H) -quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene. Cancer Lett 1997; 112: 181-189.
36. Harada K, Supriatno, Yoshida H, Sato M. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8. Int J Oncol 2005; 27: 1489-1497.